Clarus Therapeutics Holdings Inc - Class A

Research Clarus Therapeutics Holdings Inc - Class A (BLUW) on Bullrun: valuation model: 21.9% undervalued, market cap USD 333.74M, P/E 46.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBLUW
• ExchangeNASDAQ
• CountryUnited States
• SectorFinancial Services
• IndustryShell Companies
• CurrencyUSD
• Valuation signal21.9% undervalued
• Market capUSD 333.74M
• P/E46.6
• Financial periodFY2025
• Net incomeUSD 4.67M

Valuation Snapshot

Bullrun's latest valuation model marks Clarus Therapeutics Holdings Inc - Class A as 21.9% undervalued; latest market cap is USD 333.74M; P/E is 46.6.

About Clarus Therapeutics Holdings Inc - Class A

Blue Water Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to target businesses in the artificial intelligence, biotechnology, healthcare, and technology sectors. Blue Water Acquisition Corp. III was incorporated in 2024 and is based in Mountainside, New Jersey.

Frequently asked questions

Is Clarus Therapeutics Holdings Inc - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Clarus Therapeutics Holdings Inc - Class A as 21.9% undervalued.

What is Clarus Therapeutics Holdings Inc - Class A's market cap?

Clarus Therapeutics Holdings Inc - Class A's market capitalization is USD 333.74M.

What is Clarus Therapeutics Holdings Inc - Class A's P/E ratio?

Clarus Therapeutics Holdings Inc - Class A's price-to-earnings (P/E) ratio is 46.6.

What does Clarus Therapeutics Holdings Inc - Class A do?

Blue Water Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses.